Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up

Hudecova, Miriam; Holte, Jan; Olovsson, Matts; Larsson, Anders; Berne, Christian; Sundström‐Poromaa, Inger

doi:10.1016/j.fertnstert.2011.08.006

Cited by 53 publications

(62 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that older patients are more often diagnosed with idiopathic hirsutism due to improved ovulation rate and decreased ovarian volume [ 21 ] . In agreement with this hypothesis, Hudecova reported that only 36.5 % women with PCOS still fulfi lled the PCOS criteria after on average 14 years of follow-up [ 22 ] .…”

Section: Pco Is a Normal Variant During Transvaginal Us And In A Recentmentioning

confidence: 53%

Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors During Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome

et al. 2012

View full text Add to dashboard Cite

Clinical manifestations and metabolic risk factors may differ according to age in patients with polycystic ovary syndrome (PCOS). Therefore, a retrospective trans-sectional study in academic tertiary-care medical center was designed. A cohort of 446 premenopausal, Caucasian women (age range 15-49 years) with PCOS were divided into 4 subgroups according to age: group 1 (15-19 years, n=42), group 2 (20-29 years, n=180), group 3 (30-39 years, n=187), group 4 (40-49 years, n=37) and underwent clinical evaluation (Ferriman-Gallwey score, BMI, waist, blood pressure), hormone analyses (sex hormones, fasting lipids, insulin, glucose), transvaginal ultrasound, oral glucose tolerance tests (OGTT) (n=234), and ACTH tests (n=201). BMI, waist, Ferriman-Gallwey score, blood pressure, and lipid profile were higher in older vs. younger age groups whereas androgen levels were lower. Measures of insulin resistance were unchanged between age groups, but glucose levels were significantly higher in older age groups. Rotterdam criteria: The prevalence of PCO and biochemical hyperandrogenism decreased in the oldest age group whereas clinical hyperandrogenism increased. Young patients are characterized by PCO and biochemical hyperandrogenism, whereas older patients are more obese with more severe hirsutism and more cardiovascular and metabolic risk factors.

show abstract

Section: Pco Is a Normal Variant During Transvaginal Us And In A Recentmentioning

confidence: 53%

Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors During Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Furthermore, in 43-year-old women previously diagnosed with PCOS and with a mean BMI of 28.3 kg/m 2 , the metabolic syndrome occurred after a mean follow-up of 13.9 years in only 23.8% (107). This was probably the consequence of lower BMI values in this population of Swedish women.…”

Section: Metabolic Risksmentioning

confidence: 78%

MECHANISMS IN ENDOCRINOLOGY: Thyroid and polycystic ovary syndrome

Gaberšček

Zaletel

Schwetz

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Thyroid disorders, especially Hashimoto's thyroiditis (HT), and polycystic ovary syndrome (PCOS) are closely associated, based on a number of studies showing a significantly higher prevalence of HT in women with PCOS than in controls. However, the mechanisms of this association are not as clear. Certainly, genetic susceptibility contributes an important part to the development of HT and PCOS. However, a common genetic background has not yet been established. Polymorphisms of the PCOS-related gene for fibrillin 3 (FBN3) could be involved in the pathogenesis of HT and PCOS. Fibrillins influence the activity of transforming growth factor beta (TGFb). Multifunctional TGFb is also a key regulator of immune tolerance by stimulating regulatory T cells (Tregs), which are known to inhibit excessive immune response. With lower TGFb and Treg levels, the autoimmune processes, well known in HT and assumed in PCOS, might develop. In fact, lower levels of TGFb1 were found in HT as well as in PCOS women carrying allele 8 of D19S884 in the FBN3 gene. Additionally, vitamin D deficiency was shown to decrease Tregs. Finally, high estrogen-to-progesterone ratio owing to anovulatory cycles in PCOS women could enhance the immune response. Harmful metabolic and reproductive effects were shown to be more pronounced in women with HT and PCOS when compared with women with HT alone or with controls. In conclusion, HT and PCOS are associated not only with respect to their prevalence, but also with regard to etiology and clinical consequences. However, a possible crosstalk of this association is yet to be elucidated.

show abstract

“…However, the impact of dyslipidaemia in different PCOS phenotypes is not known. Metabolic abnormalities including dyslipidaemia seem to be transmitted to first-degree relatives of women with PCOS (177) and may deteriorate with obesity (176) and ageing (178). Nevertheless, the influence of BMI on the severity of dyslipidaemia is still controversial and may be influenced by the origin of investigated PCOS women (177,178).…”

Section: Role Of Lipo-oxidative Stressmentioning

confidence: 99%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

576

492

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.

show abstract

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up

Cited by 53 publications

References 16 publications

Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors During Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome

Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors During Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome

MECHANISMS IN ENDOCRINOLOGY: Thyroid and polycystic ovary syndrome

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Contact Info

Product

Resources

About